Target type: biologicalprocess
Any process that decreases the rate, frequency or extent of secretion of lysosomal enzymes, the controlled release of lysosomal enzymes by a cell. [GOC:BHF]
Negative regulation of secretion of lysosomal enzymes is a complex process that involves a coordinated interplay of various cellular mechanisms. Lysosomal enzymes, which are essential for intracellular degradation and recycling, are synthesized in the endoplasmic reticulum (ER) and subsequently transported through the Golgi apparatus to lysosomes. However, the release of these enzymes into the extracellular space can be detrimental, leading to cellular damage and inflammation. Therefore, cells have evolved intricate regulatory pathways to tightly control the secretion of lysosomal enzymes.
One crucial mechanism involves the regulation of lysosomal enzyme trafficking through the secretory pathway. Lysosomes are acidic organelles that maintain a low pH, and this acidic environment is essential for the proper functioning of lysosomal enzymes. The pH of the lysosomal lumen is regulated by proton pumps, which pump protons into the lysosome, lowering its pH. Changes in the pH of the lysosome can affect the activity of lysosomal enzymes and their trafficking through the secretory pathway.
Another important aspect of negative regulation is the sorting of lysosomal enzymes. Specific sorting signals embedded in the lysosomal enzyme proteins guide their trafficking to lysosomes. These signals can be recognized by adaptor proteins that facilitate the packaging of lysosomal enzymes into transport vesicles. Mutations in these sorting signals or in the adaptor proteins can lead to the misdirection of lysosomal enzymes, resulting in their secretion instead of delivery to lysosomes.
In addition to the sorting and trafficking of lysosomal enzymes, the secretion of these enzymes can be regulated by various signaling pathways. For example, growth factors and other stimuli can trigger the activation of signaling cascades that lead to the phosphorylation of specific proteins involved in lysosomal enzyme trafficking. These phosphorylation events can alter the interactions between lysosomal enzymes and their transport machinery, ultimately affecting the efficiency of lysosomal enzyme secretion.
Furthermore, the secretion of lysosomal enzymes can be modulated by the cellular environment. Cells can respond to stress conditions, such as hypoxia or nutrient deprivation, by altering the secretion of lysosomal enzymes. For example, under conditions of nutrient deprivation, cells may increase the secretion of lysosomal enzymes to break down extracellular components and provide a source of nutrients.
In conclusion, negative regulation of secretion of lysosomal enzymes involves a multifaceted process that ensures the proper delivery and retention of these enzymes within lysosomes. This tight control is essential for maintaining cellular homeostasis and preventing the detrimental effects of lysosomal enzyme leakage into the extracellular space.'
"
Protein | Definition | Taxonomy |
---|---|---|
Oxysterols receptor LXR-alpha | An oxysterols receptor LXR-alpha that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q13133] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
1-deoxynojirimycin | 1-deoxy-nojirimycin: structure in first source duvoglustat : An optically active form of 2-(hydroxymethyl)piperidine-3,4,5-triol having 2R,3R,4R,5S-configuration. | 2-(hydroxymethyl)piperidine-3,4,5-triol; piperidine alkaloid | anti-HIV agent; anti-obesity agent; bacterial metabolite; EC 3.2.1.20 (alpha-glucosidase) inhibitor; hepatoprotective agent; hypoglycemic agent; plant metabolite |
betulinic acid | hydroxy monocarboxylic acid; pentacyclic triterpenoid | anti-HIV agent; anti-inflammatory agent; antimalarial; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; plant metabolite | |
25-hydroxycholesterol | 25-hydroxy steroid; oxysterol | human metabolite | |
bexarotene | benzoic acids; naphthalenes; retinoid | antineoplastic agent | |
3 beta-hydroxy-delta 5-cholenic acid | steroid | ||
podocarpic acid | podocarpic acid : An abietane diterpenoid lacking the isopropyl substituent with an aromatic C-ring and a hydroxy group at the 12-position. podocarpic acid: structure | abietane diterpenoid | |
(20s)-20-hydroxycholesterol | 20-hydroxycholesterol : An oxysterol that is cholesterol substituted by a hydroxy group at position 20. 20-hydroxycholesterol: RN given refers to (20S)-isomer | 20-hydroxy steroid; 3beta-hydroxy-Delta(5)-steroid; oxysterol | human metabolite; mouse metabolite |
24-hydroxycholesterol | (24S)-24-hydroxycholesterol : A 24-hydroxycholesterol that has S configuration at position 24. It is the major metabolic breakdown product of cholesterol in the brain. | 24-hydroxycholesterol | biomarker; human blood serum metabolite; mouse metabolite |
27-hydroxycholesterol | (25R)-cholest-5-ene-3beta,26-diol : A 26-hydroxycholesterol in which the 25-position has R-configuration. | 26-hydroxycholesterol | apoptosis inducer; human metabolite; mouse metabolite; neuroprotective agent |
cyanidin | cyanidin cation : An anthocyanidin cation that is flavylium substituted at positions 3, 3', 4', 5 and 7 by hydroxy groups. cyanidin: RN given refers to parent cpd; structure | 5-hydroxyanthocyanidin | antioxidant; metabolite; neuroprotective agent |
(22r)-22-hydroxycholesterol | (22R)-22-hydroxycholesterol : An oxysterol that is the 22R-hydroxy derivative of cholesterol. | 22-hydroxy steroid; 3beta-hydroxy-Delta(5)-steroid; oxysterol | |
22s-hydroxycholesterol | (22S)-22-hydroxycholesterol : An oxysterol that is the 22S-hydroxy derivative of cholesterol. | 22-hydroxy steroid; 3beta-hydroxy-Delta(5)-steroid; oxysterol | |
gw 3965 | GW 3965: a liver X receptor ligand | diarylmethane | |
t0901317 | T0901317: an LXRalpha and LXRbeta agonist | ||
alitretinoin | Alitretinoin: A retinoid that is used for the treatment of chronic hand ECZEMA unresponsive to topical CORTICOSTEROIDS. It is also used to treat cutaneous lesions associated with AIDS-related KAPOSI SARCOMA. | retinoic acid | antineoplastic agent; keratolytic drug; metabolite; retinoid X receptor agonist |
24,25-epoxycholesterol | 24,25-epoxycholesterol: Rn given refers to (3alpha,5beta)-isomer; structure given in first source 24(S),25-epoxycholesterol : A 3beta-hydroxy-Delta(5)-steroid that is desmosterol in which the double bond at position 24-25 has been oxidised to the corresponding epoxide (the 24S diastereoisomer). It is an oxysterol agonist of the liver X receptor. | 3beta-hydroxy-Delta(5)-steroid; cholestanoid; epoxy steroid | liver X receptor agonist |
genistein | 7-hydroxyisoflavones | antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor | |
piericidin a | piericidin A : A member of the class of monohydroxypyridines that acts as an irreversible mitochondrial Complex I inhibitor that strongly associates with ubiquinone binding sites in both mitochondrial and bacterial forms of NADH:ubiquinone oxidoreductase piericidin A: pyridine-substituted fatty alcohol antibiotic; minor descriptor (75-85); on-line & Index Medicus search ANTIBIOTICS (75-85); RN given refers to (S-(R*,R*-(all-E)))-isomer | aromatic ether; methylpyridines; monohydroxypyridine; secondary allylic alcohol | antimicrobial agent; bacterial metabolite; EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitor; mitochondrial respiratory-chain inhibitor |
pregna-4,17-diene-3,16-dione | pregna-4,17-diene-3,16-dione: steroid from guggulu extract; RN & N1 from C1 Form index; RN given refers to cpd without isomeric designation; structure in first source; antagonist of farnesoid X receptor | 3-hydroxy steroid | androgen |
acanthoic acid | acanthoic acid: from root bark of Acanthopanax koreanum; structure given in first source | ||
3-chloro-4-(3-(7-propyl-3-trifluoromethyl-6-benzisoxazolyl)propylthio)phenylacetic acid | |||
riccardin c | riccardin C: isolated from liverworts; functions as a liver X receptor (LXR)alpha agonist and an LXRbeta antagonist; structure in first source | ||
bms 687453 | |||
way 252623 | 2-(2-chloro-4-fluorobenzyl)-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole: a partial LXR agonist | ||
cholenic acid dimethylamide | cholenic acid dimethylamide: binds LXRalpha receptor; structure in first source | ||
glucopiericidin a | glucopiericidin A: from Streptomyces pactum S48727 as co-metabolite of piericidin A(1); structure given in first source; glycoside antibiotic | ||
gsk4112 | GSK4112: a Rev-erbalpha agonist; structure in first source | ||
sr9009 | |||
sr9011 | SR9011: a REV-ERB agonist; structure in first source | ||
sr9238 | SR9238: liver-selective LXR inverse agonist that suppresses hepatic steatosis; structure in first source |